TPI Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from China's SFDA

by Benzinga Staff
June 1, 2011 7:33 AM | 9 seconds read |
Tianyin Pharmaceutical Co., Inc. TPI today announced TPI has received the production license for its anti-diabetic drug Gliclazide Tablets from China's State Food and Drug Administration.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDAHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!